


## Artificial Pancreas Devices Systems Market Set to Surge to \$0.8 Billion by 2033 at a 8.8% CAGR

The Artificial Pancreas Devices Systems Market is expected to reach \$0.8 billion by 2033, growing at a CAGR of 8.8% from 2024 to 2033.

WILMINGTON, DE, UNITED STATES, March 19, 2025 /EINPresswire.com/ --As of 2023, the <u>Artificial Pancreas</u> <u>Devices Systems Market</u> was valued at approximately \$0.4 billion. Projections indicate that this market is expected to



reach \$0.8 billion by 2033, growing at a CAGR of 8.8% from 2024 to 2033. The Artificial Pancreas Devices Systems Market has been experiencing significant growth, driven by technological advancements and the increasing prevalence of diabetes worldwide. These devices, designed to automate blood glucose control, offer a promising solution for individuals managing diabetes.

Get Sample PDF Copy: <u>https://www.alliedmarketresearch.com/request-sample/A324367</u>

## Artificial Pancreas Devices Systems Market Growth Factors

Several key factors contribute to the growth of the Artificial Pancreas Devices Systems Market: 1. Rising Prevalence of Diabetes: The increasing number of individuals diagnosed with diabetes, particularly type 1 diabetes, has heightened the demand for advanced management solutions. 2. Technological Advancements: Continuous innovations in glucose monitoring and insulin delivery technologies have led to more efficient and user-friendly artificial pancreas systems. 3. Increased Awareness: Growing awareness about diabetes management and the benefits of artificial pancreas devices among patients and healthcare providers has boosted market adoption.

 Government Initiatives: Supportive government policies and funding for diabetes care and research have facilitated the development and adoption of artificial pancreas technologies.
Integration with Digital Health: The convergence of artificial pancreas devices with digital health platforms allows for real-time monitoring and data analysis, enhancing patient outcomes. Artificial Pancreas Devices Systems Market Segmentation

The Artificial Pancreas Devices Systems Market is segmented based on device type and end user:

1. By Device Type:

D Threshold Suspend Device Systems: These systems temporarily suspend insulin delivery when glucose levels drop below a predefined threshold, reducing the risk of hypoglycemia.

□ Control-To-Range (CTR) Systems: CTR systems adjust insulin delivery to maintain glucose levels within a specified range, providing more precise glucose control.

Control-To-Target (CTT) Systems: CTT systems aim to achieve a specific glucose target by continuously adjusting insulin delivery based on real-time glucose readings.

2. By End User:

Despitals: Hospitals utilize artificial pancreas devices for in-patient diabetes management, ensuring optimal glucose control during hospital stays.

□ Clinics: Outpatient clinics employ these devices for regular monitoring and management of patients with diabetes.

□ Homecare: Homecare settings have seen increased adoption of artificial pancreas devices, allowing patients to manage their condition in the comfort of their homes.

Have Any Query? Ask Our Experts: <u>https://www.alliedmarketresearch.com/purchase-enquiry/A324367</u>

Key Players in the Artificial Pancreas Devices Systems Market

Several companies are leading the development and commercialization of artificial pancreas devices:

- Medtronic Plc
- Bigfoot Biomedical
- Johnson & Johnson
- Tandem Diabetes Care, Inc.
- Pancreum, Inc.
- TypeZero Technologies, LLC
- Beta Bionics
- Insulet Corporation
- Diabeloop
- Inreda Diabetic

## Recent Developments

In January 2024, Medtronic Plc announced the CE Mark approval for its MiniMed 780G system with Simplera Sync, a disposable, all-in-one continuous glucose monitor (CGM) requiring no fingersticks or overtape. Simplera Sync features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors.

The Artificial Pancreas Devices Systems Market is poised for substantial growth, driven by

technological innovations, increasing diabetes prevalence, and a greater emphasis on effective disease management. As key players continue to develop and refine these systems, artificial pancreas devices are expected to become integral components of diabetes care, improving the quality of life for millions worldwide.

Procure Complete Report: <u>https://www.alliedmarketresearch.com/artificial-pancreas-devices-</u> systems-market/purchase-options

Thanks for reading this article; you can also get an individual chapter-wise sections or regionwise report versions like North America, LATAM, Europe, or Southeast Asia.

## About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa Allied Market Research + 1800-792-5285 email us here Visit us on social media: Facebook X LinkedIn YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/795335096

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire<sup>™</sup>, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.